For the quarter ended June 2025, United Therapeutics (UTHR) reported revenue of $798.6 million, up 11.7% over the same period last year. EPS came in at $6.41, compared to $5.85 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $795.75 million, representing a surprise of +0.36%. The company delivered an EPS surprise of -5.74%, with the consensus EPS estimate being $6.80.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how United Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- United States: $759.8 million versus $749.74 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +12.5% change.
- Revenues- Rest-of-World: $38.8 million compared to the $33.98 million average estimate based on three analysts. The reported number represents a change of -2.3% year over year.
- Revenues- Tyvaso- U.S.: $455.3 million compared to the $452.61 million average estimate based on two analysts.
- Revenues- Unituxin- U.S.: $55.4 million versus the two-analyst average estimate of $53.07 million.
- Revenues- Adcirca: $6.5 million compared to the $4.81 million average estimate based on seven analysts. The reported number represents a change of +14% year over year.
- Revenues- Orenitram: $123.9 million versus $118.65 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +15.7% change.
- Revenues- Tyvaso: $469.6 million versus the six-analyst average estimate of $473.16 million. The reported number represents a year-over-year change of +17.9%.
- Revenues- Remodulin: $134.7 million compared to the $137.99 million average estimate based on six analysts. The reported number represents a change of -8.6% year over year.
- Revenues- Unituxin: $58.4 million versus the six-analyst average estimate of $55.58 million. The reported number represents a year-over-year change of +13%.
- Revenues- Tyvaso DPI: $315.2 million compared to the $313.48 million average estimate based on five analysts.
- Revenues- Nebulized Tyvaso: $154.4 million versus $154.53 million estimated by five analysts on average.
- Revenues- Other products: $5.5 million versus the four-analyst average estimate of $4.95 million. The reported number represents a year-over-year change of +12.2%.
View all Key Company Metrics for United Therapeutics here>>>
Shares of United Therapeutics have returned +2.3% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
United Therapeutics Corporation (UTHR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
